Where is the Place of Surgery for N2 Disease?

被引：0
|
作者：
Van Schil, Paul [1 ]
Faivre-Finn, Corinne [2 ,3 ]
机构：
[1] Antwerp Univ Hosp, Thorac & Vasc Surg, Antwerp, Belgium
[2] Univ Manchester, Radiotherapy Res Related, Manchester, Lancs, England
[3] Christie NHS Fdn Trust, Manchester, Lancs, England
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期
关键词：
induction therapy; Chemo-radiotherapy; Surgery; stage IIIA-N2 disease; CELL LUNG-CANCER; SALVAGE SURGERY; RADIOTHERAPY; CHEMOTHERAPY; GUIDELINES;
D O I：
10.1016/j.jtho.2016.11.138
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MTE05.01
引用
收藏
页码：S152 / S154
页数：3
相关论文
共 50 条
  • [31] Stage 3 N2 Lung Cancer: A Multidisciplinary Therapeutic Conundrum
    Carter, Lily
    Apte, Vedika
    Shukla, Arushi
    Ghose, Aruni
    Mamidi, Raj
    Petohazi, Alexandra
    Makker, Shania
    Banerjee, Soirindhri
    Boussios, Stergios
    Banna, Giuseppe L.
    CURRENT ONCOLOGY REPORTS, 2024, 26 (01) : 65 - 79
  • [32] Persistent N2 After Induction Is Not a Contraindication to Surgery for Lung Cancer
    Andrews, Weston G.
    Louie, Brian E.
    Castiglioni, Massimo
    Dhamija, Ankit
    Farivar, Alex S.
    Chansky, Joshua
    White, Peter T.
    Aye, Ralph W.
    Vallieres, Eric
    Bograd, Adam J.
    ANNALS OF THORACIC SURGERY, 2022, 114 (02) : 394 - 400
  • [33] Which N2 Patients Are Candidates to Surgery in the Era If I/O?
    Vallieres, E.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S69 - S70
  • [34] Induction Therapies Plus Surgery Versus Exclusive Radiochemotherapy in Stage IIIA/N2 Non-Small Cell Lung Cancer (NSCLC)
    Jeremic, Branislav
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2018, 41 (03): : 267 - 273
  • [35] PREOPERATIVE CHEMOTHERAPY VERSUS PREOPERATIVE CHEMORADIOTHERNPY FOR STAGE III (N2) NON-SMALL-CELL LUNG CANCER
    Higgins, Kristin
    Chino, Junzo P.
    Marks, Lawrence B.
    Ready, Neal
    D'Amico, Thomas A.
    Clough, Robert W.
    Kelsey, Chris R.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (05): : 1462 - 1467
  • [36] Is single-station N2 disease on PET-CT an indication for primary surgery in lung cancer patients?
    Kowalewski, Janusz
    Szczesny, Tomasz J.
    JOURNAL OF THORACIC DISEASE, 2017, 9 (12) : 4828 - 4831
  • [37] Upfront surgery in patients with clinical skip N2 lung cancer based on results of modern radiological examinations
    Maniwa, Tomohiro
    Shintani, Yasushi
    Okami, Jiro
    Kadota, Yoshihisa
    Takeuchi, Yukiyasu
    Takami, Koji
    Yokouchi, Hideoki
    Kurokawa, Eiji
    Kanzaki, Ryu
    Sakamaki, Yasushi
    Shiono, Hiroyuki
    Iwasaki, Teruo
    Nishioka, Kiyonori
    Kodama, Ken
    Okumura, Meinoshin
    JOURNAL OF THORACIC DISEASE, 2018, 10 (12) : 6828 - 6837
  • [38] Upfront surgery for N2 NSCLC: a large retrospective multicenter cohort study
    Alessio Campisi
    Chiara Catelli
    Piotr Gabryel
    Riccardo Giovannetti
    Andrea Dell’Amore
    Mariusz Kasprzyk
    Cezary Piwkowski
    Maurizio Infante
    General Thoracic and Cardiovascular Surgery, 2023, 71 : 715 - 722
  • [39] Additional adjuvant radiotherapy improves survival at 1 year after surgical treatment for pancreatic cancer patients with T4, N2 disease, positive resection margin, and receiving adjuvant chemotherapy
    Wu, Lili
    Xu, Yaolin
    Zhou, Yuhong
    Zeng, Zhaochong
    Fan, Yue
    Wang, Dansong
    Wu, Wenchuan
    Guo, Xi
    Lv, Minzhi
    Ouyang, Yuxiu
    Du, Shisuo
    Lou, Wenhui
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [40] Lung Cancer: Is Surgery an Option for Persisting N2 after Induction Therapy?
    Haager, B.
    Osei-Agyemang, T.
    Passlick, B.
    Wiesemann, S.
    ZENTRALBLATT FUR CHIRURGIE, 2015, 140 (01): : 99 - 103
12345